The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
dapagliflozin
Class :
Antidiabetics, SGLT2 Inhibitors
Brand Name :
No Data Available.
Synonyms :
dapagliflozin
Class :
Antidiabetics, SGLT2 Inhibitors
Dosage forms & StrengthsÂ
TabletÂ
5mgÂ
10mgÂ
5 mg orally once daily to improve the glycemic control
May increase the dose to 10 mg once daily for an additional effect, if the lower dose is tolerated
Congestive Heart Failure (CHF)Â
To reduce the risk of hospital admission in case of heart failure, dapagliflozin is indicated 10 mg orally in the morning
In the case of renal impairment when eGFR ≥45mL/min/1.73 m2 no dose adjustment is required
When eGFR ranges from 25 to 45 mL/min/1.732 m2 no dose adjustment is required
When eGFR <25mL/min/1.73 m2 the patients with heart failure or chronic kidney disease may continue the dose at 10 mg/day to minimize the risk of eGFR decline, cardiovascular death, and heart failure accompanying hospitalization
The drug is contraindicated during dia:
dapagliflozin is indicated in the patients with chronic kidney disease to reduce the risk of eGFR decline
10 mg orally each day
Safety and efficacy are not seen in pediatric patients Â
Refer to the adult dosingÂ
dapagliflozin: it may increase the risk or severity of QTc prolongation
dapagliflozin: it may increase the risk or severity of QTc prolongation
dapagliflozin: it may increase the risk or severity of QTc prolongation
dapagliflozin: it may increase the risk or severity of QTc prolongation
dapagliflozin: it may increase the risk or severity of QTc prolongation
may increase the hypoglycemic effect
may increase the hypoglycemic effect
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Combining dapagliflozin with pranlukast may cause a reduction in the dapagliflozin’s metabolism
when bromazepam and dapagliflozin are used together, there is a potential reduction in the bromazepam's metabolism
When helometasone is used together with dapagliflozin, this leads to elevated risk or seriousness of hyperglycemia
dapagliflozin: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
dapagliflozin: it may increase the risk or severity of CNS depression
the potential or intensity of hyperglycemia can be heightened when flurandrenolide is combined with dapagliflozin
When dapagliflozin is used together with diazoxide, this leads to reduction in therapeutic effectiveness of dapagliflozin
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with dapagliflozin, this leads to elevated hyperglycemia risk
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the hypoglycemic effect
may decrease the therapeutic effect
the risk of hyperglycemia may be increased
When dapagliflozin is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
the anti-diabetic efficacy of dapagliflozin can be reduced with mometasone furoate
Actions and Spectrum:Â
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, selectively blocks glucose reabsorption in the kidneys that leading to increased urinary glucose excretion and reduced blood glucose levels. It also promotes weight loss by increasing urine excretion of glucose and fat derived calories. Â
It reduces blood pressure in type 2 diabetes patients due to its diuretic effect and improvement in arterial stiffness. Clinical trials show that dapagliflozin reduces the risk of cardiovascular events including heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Â
It also slows the progression of kidney disease in patients with type 2 diabetes and established kidney disease. Â
Dapagliflozin may reduce the risk of hypoglycemia when used as monotherapy or in combination with insulin or insulin secretagogues.Â
Frequency DefinedÂ
>10%Â
Renal impairmentÂ
1-10%Â
Nasopharyngitis Â
Urinary tract infection Â
Back pain Â
Increased urination Â
Dyslipidemia Â
Influenza Â
Female genital mycotic infections Â
Male genital mycotic infections Â
Nausea Â
Discomfort with urinationÂ
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â
Dapagliflozin causes serious side effects like hypotension, hypertension, ketoacidosis, genital mycotic infections, and hypoglycemia. Â
It is particularly dangerous in patients with severe renal impairment, end-stage renal disease, or those on dialysis. Â
Patients should also be aware of their known hypersensitivity to dapagliflozin. Â
Adequate hydration is crucial, as dapagliflozin may increase the risk of hypotension especially in patients taking diuretics or renal impairment. Regular monitoring of blood pressure is essential, as dapagliflozin may also decrease blood pressure in patients taking antihypertensive medications. It may increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues like sulfonylureas.Â
Pregnancy/Lactation Â
Pregnancy consideration: Â
It is not secure to administer dapagliflozin during pregnancy.Â
Breastfeeding warnings: Â
No data is available about the excretion of dapagliflozin in human breastmilk. Avoid using in lactating women.Â
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.Â
Category B: No evidence of risk to the fetus is found in animal reproduction studies, and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a human product; Pregnant women must take care of the potential risks.Â
Category D: There is adequate data with sufficient evidence of human fetal risk from various platforms. However, despite potential dangers may be used only in emergencies for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. The drug is not for pregnant women.Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
It is a type 2 diabetes medication that decreases blood glucose levels and reduce HbA1c levels and is quickly absorbed after oral administration with peak plasma concentrations reaching within 2 hours.Â
Pharmacodynamics:Â
Dapagliflozin is a selective SGLT2 inhibitor this improves glycemic control in type 2 diabetes patients by blocking glucose reabsorption by the kidneys. This leads to increased urinary glucose excretion and reduced blood glucose levels. It also had beneficial effects on cardiovascular and renal outcomes by reducing the risk of cardiovascular death or heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.Â
This has positive effects on body weight, blood pressure, and lipid profiles in patients with type 2 diabetes.Â
Its rapid onset results in a reduction in blood glucose levels within the first week of treatment but its effects on cardiovascular and renal outcomes may take longer due to its long-term effects on glucose control and other metabolic parameters.Â
Pharmacokinetics:Â
AbsorptionÂ
The bioavailability is 78%Â
The peak plasma concentration is achieved in 2 hours (for fasting) and around 3 hours (with high fat meal)Â
DistributionÂ
The protein bound is 91%Â
MetabolismÂ
The metabolism is primarily mediated by UGT1A9Â
The drug is extensively metabolized primarily to produce dapagliflozin 3-O-glucuronide Â
Elimination and ExcretionÂ
The half-life is 12.9 hoursÂ
The drug is excreted 75% in urine and 21% fecesÂ
Administration:Â
It is an oral drug used to treat type 2 diabetes the usual dose is 5 mg once a day with the possibility of increasing to 10 mg if needed.
It can be taken W or W/o food and should be swallowed whole with water.
Regular monitoring of blood sugar levels is essential to avoid the risk of ketoacidosis that can lead to coma or death.
Dapagliflozin can also increase the risk of urinary tract and genital infections especially in women.Â
 Â
Patient information leafletÂ
Generic Name: dapagliflozin
Pronounced: dap-a-glif-lozin
Why do we use dapagliflozin?Â
Dapagliflozin is a SGLT2 inhibitors which works by blocking glucose reabsorption by the kidneys that resulting in increased urine glucose excretion and lower blood sugar levels. Â
It is primarily used to treat type 2 diabetes and may be combined with other drugs to treat heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) in adults with type 2 diabetes. Â
This drug should not be used for type 1 diabetes, severe kidney impairment, diabetic ketoacidosis, end-stage renal disease (ESRD), and dialysis. Additionally, dapagliflozin may cause side effects like dehydration, urinary tract infections, and yeast infections, it should be used with caution and under healthcare provider supervision.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
